AbbVie Unit Launches Patent Suit Over Cancer Drug
AbbVie's Pharmacyclics unit has alleged in a new suit that its recently issued patent relating to its cancer drug Imbruvica is being infringed by a BeiGene product that got approval from...To view the full article, register now.
Already a subscriber? Click here to view full article